Medicago: Publication of phase III COVID-19 vaccine study results of Covifenz in New England Journal of Medicine.

Medicago announced the publication of the results from the Phase III study of Covifenz, COVID-19 Vaccine (plant-based virus-like particles [VLP], recombinant, adjuvanted), in the New England Journal of Medicine (NEJM). The Phase III trial studied the two-dose regimen of Covifenz given 21 days apart versus placebo in over 24,000 subjects aged 18 and above.